Drug multinationals are treading with caution on the molecules to license from Indian companies, meaning Glenmark’s deal with France’s Sanofi may not be a forerunner to a clutch of similar agreements benefiting local firms.
Indian pharmaceutical companies outlicense a drug under development to foreign players with deep pockets as it is an expensive process. The latter undertakes trials to develop the drug.
Indian pharmaceutical companies outlicense a drug under development to foreign players with deep pockets as it is an expensive process. The latter undertakes trials to develop the drug.
